Proportion of patients achieving ACR20 at week 24 and week 48
| HD203 | Enbrel® | Difference (95% CI) | P-value | |
|---|---|---|---|---|
| 24-week PPS | 83.48% (96/115) | 81.36% (96/118) | 2.12 (−7.65, 11.89) | 0.6706† |
| FAS | 79.10% (106/134) | 75.56% (102/135) | 3.55 (−6.45, 13.55) | 0.4870† |
| 48-week PPS | 86.27% (88/102) | 81.90% (86/105) | 4.37 (−5.57, 14.31) | 0.3905† |
CI, confidence interval; PPS, per-protocol set; FAS, full analysis set; †Pearson's chi-square test.